Balyasny Asset Management L.P. Invests $133,000 in Bioventus Inc. (NYSE:BVS)

Balyasny Asset Management L.P. acquired a new stake in shares of Bioventus Inc. (NYSE:BVS) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 12,651 shares of the company’s stock, valued at approximately $133,000.

Other institutional investors also recently modified their holdings of the company. Tower Research Capital LLC TRC increased its position in Bioventus by 106.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,469 shares of the company’s stock valued at $36,000 after acquiring an additional 1,786 shares during the last quarter. Plato Investment Management Ltd bought a new stake in shares of Bioventus during the 4th quarter valued at about $38,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Bioventus during the 4th quarter valued at about $75,000. Quantbot Technologies LP bought a new position in shares of Bioventus in the 4th quarter worth approximately $103,000. Finally, Arizona State Retirement System purchased a new position in shares of Bioventus in the fourth quarter worth approximately $109,000. 62.94% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

BVS has been the subject of a number of research reports. Craig Hallum set a $15.00 target price on shares of Bioventus and gave the company a “buy” rating in a report on Wednesday, May 7th. Canaccord Genuity Group reissued a “buy” rating and set a $15.00 price objective on shares of Bioventus in a research report on Monday, March 17th.

Insider Buying and Selling

In other news, SVP Anthony D’adamio sold 4,380 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total value of $44,632.20. Following the transaction, the senior vice president now directly owns 118,178 shares in the company, valued at $1,204,233.82. The trade was a 3.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Mark Leonard Singleton sold 3,875 shares of the company’s stock in a transaction dated Friday, April 11th. The stock was sold at an average price of $7.57, for a total value of $29,333.75. Following the completion of the transaction, the chief financial officer now directly owns 141,088 shares of the company’s stock, valued at approximately $1,068,036.16. This trade represents a 2.67% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 24,208 shares of company stock valued at $226,138. 32.90% of the stock is owned by corporate insiders.

Bioventus Stock Up 3.8%

NYSE BVS opened at $6.79 on Monday. Bioventus Inc. has a 52 week low of $5.28 and a 52 week high of $14.38. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85. The company has a market capitalization of $556.40 million, a P/E ratio of -11.13 and a beta of 0.95. The stock’s 50-day moving average price is $8.09 and its 200-day moving average price is $9.81.

Bioventus Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.